BioWorld

Jan. 15, 2004

Adolor's Stock Suffers After Last Entereg Phase III Fails

Despite mediocre results from their fourth Phase III trial, Adolor Corp. and partner GlaxoSmithKline plc expect to seek regulatory approval this year for Entereg in the management of postoperative ileus. (BioWorld Today) Read More

Amgen's CEO Chides Leaders For 'Hiding' From Ethics Fray

OxiGene Gets $22.3M, Plans Expansion Of CA4P Program

Enanta Raises $12M To Further Macrolide Respiratory Program

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 8, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 8, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

ASH 2025: New blood cancer therapies trump chemo, older drugs

BioWorld

Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...